Clinical trial
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal…
NCT00107861 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00107861 |
|---|---|
| Title | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases |
| Official title | A Phase I/II Study of Interferon-Beta Gene Transfer (Ad.hIFN-β) in the Treatment of Refractory Colorectal Carcinoma With Liver Metastases |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Carcinoma, Metastases |
| Intervention type | Drug |
| Interventions | Ad.hIFN-β (BG00001, IDEC-201) |
| Enrollment | 44 |
| Start date | May 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Apr 12, 2005 |
| Last update posted | Jul 14, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: